Hyperion Therapeutics to Present at the Eighth Annual JMP 2013 Global Healthcare Securities Conference

Hyperion Therapeutics to Present at the Eighth Annual JMP 2013 Global
Healthcare Securities Conference

SOUTH SAN FRANCISCO, Calif., July 2, 2013 (GLOBE NEWSWIRE) -- Hyperion
Therapeutics (Nasdaq:HPTX) announced today that the company is scheduled to
present at the eighth annual JMP 2013 Global Healthcare Securities Conference
on Wednesday, July 10 at 2:00 p.m. ET.

Donald J. Santel, Chief Executive Officer will provide a company overview. To
access the live webcast and subsequent archived recording, please visit
Hyperion's website at http://investors.hyperiontx.com/events.cfm.

About Hyperion Therapeutics
Hyperion Therapeutics, Inc. is a commercial stage biopharmaceutical company
committed to developing and delivering life-changing treatments for orphan
diseases and hepatology. The company's first commercial product, Ravicti®
(glycerol phenylbutyrate) Oral Liquid, was approved in February 2013 and is
currently being marketed in the United States. The company is also marketing
BUPHENYL® (sodium phenylbutyrate) Tablets and Powder worldwide. For more
information, please visit www.hyperiontx.com.

CONTACT: Sylvia Wheeler, Investor Relations
         (650) 794-7834
         sylvia.wheeler@hyperiontx.com
 
Press spacebar to pause and continue. Press esc to stop.